Vaccines for shingles and RSV to slow heart plaque
Part of Heart & circulation, Infections clinical trials.
This study is testing two different vaccines—one for shingles and one for RSV—to see if they can slow down build-up of plaque in the heart arteries. If you are 50 or older and have heart disease risk factors, this study may help researchers learn if these vaccines offer extra benefits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years or older.
- You must be considered stable from a medical standpoint, meaning no recent major health changes.
- You must have evidence of calcium buildup in your heart arteries, along with at least two risk factors for heart disease (like high blood pressure, high cholesterol, diabetes, smoking, or family history).
- Your kidneys must be working well enough to meet the study's requirements.
- You should not have had a major heart-related event like a heart attack or stroke, nor any heart surgery or stenting.
- You must not have received a shingles or RSV vaccine before, and you must not have a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a shingles vaccine can reduce the chance of serious heart problems in adults 50 and older who already have heart or blood vessel disease, or who have at least two risk factors like high blood pressure or diabetes. If it works, this vaccine could become a new way to protect your heart.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This study tests an RSV vaccine to see if it is safe and helps your immune system fight the virus. It's for older adults who are generally healthy, and it may help protect you from severe RSV illness.
This trial tests an experimental vaccine to protect older adults against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. It looks at whether the vaccine is safe and how well it boosts immunity. If you are healthy and over 60, you might be able to join.
This study tests an experimental vaccine to see if it is safe for healthy adults. The vaccine is made with mRNA technology and aims to protect against RSV, a common respiratory virus.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
Hear when a new Cardiovascular Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.